이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

원격으로 전달되는 필라테스가 다발성 경화증 환자의 신체적, 심리적 결과에 미치는 영향 (MS)

2026년 10월 5일 업데이트: University of Illinois Chicago

원격으로 제공되는 필라테스가 다발성 경화증 환자의 신체적 및 심리적 결과에 영향을 미치는가?

Objectives Objective 1: To determine the effects of a 16-week remotely delivered Pilates intervention on walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Objective 2: To examine the impact of a 16-week remotely delivered Pilates intervention on depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Aim Aim 1: To assess whether the 16-week remotely delivered Pilates intervention significantly improves walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS Aim 2: To investigate whether the 16-week remotely delivered Pilates intervention significantly improves depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

Hypothesis Hypothesis 1: The 16-week remotely delivered Pilates intervention will significantly improve walking endurance, walking speed, balance, fatigue, and pain compared to a waitlist control group in individuals with MS.

Hypothesis 2: Participants receiving the 16-week remotely delivered Pilates intervention will demonstrate significantly greater improvements in depression & anxiety, cognitive function, and QOL compared to a waitlist control group in individuals with MS.

연구 개요

상세 설명

The current study will determine the feasibility and efficacy of a 16-week remotely delivered Pilates intervention for improving physical and psychological outcomes, and QOL, compared with a control condition, in individuals with MS. This represents a significant step forward in examining Pilates as an accessible, complementary therapy in MS.

연구 유형

중재적

등록 (추정된)

50

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Illinois
      • Chicago, Illinois, 미국, 60612
        • 모병
        • University of Illinois Chicago
        • 연락하다:
          • Parisa Najafi, PhD
          • 전화번호: 7735055923
          • 이메일: pems@uic.edu

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 18 years or older
  • Self-reported diagnosis of multiple sclerosis by a neurologist
  • Relapse-free for the past 30 days before screening
  • Able to speak and read English as the primary language
  • Access to the internet and e-mail,
  • Ability to use Zoom, and willingness to complete testing sessions and questionnaires
  • Ambulatory without an assistive device (for example, cane)
  • Low to moderate disability, defined as a score of 0-4 on the Patient-Determined Disease Steps (PDDS)
  • Insufficiently active, defined as a score < 14 on the Godin Leisure-Time Exercise Questionnaire-Health Contribution Score (GLTEQ-HCS)
  • Adequate visual ability and literacy to read materials printed in 14-point font
  • Currently treated with a disease-modifying therapy

Exclusion Criteria:

  • Pregnant
  • Elevated risk for strenuous or maximal exercise, defined as more than one "Yes" response on the Physical Activity Readiness Questionnaire (PAR-Q) during screening

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Pilates group

Behavioral: Pilates group

REMOTLY PILATES EXERCISE

간섭 없음: Control group

Waitlist Group

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from baseline in walking endurance (Six-Minute Walk Test distance)
기간: Baseline and 16 weeks (end of treatment)

Distance walked during the Six-Minute Walk Test (6MWT) will be measured in meters. The outcome is the change from baseline to 16 weeks in 6MWT distance.

Baseline and 16 weeks (end of treatment)
Change from baseline in walking speed (Timed 25-Foot Walk)
기간: Baseline and 16 weeks (end of treatment)

Walking speed will be assessed using the Timed 25-Foot Walk (T25FW). The outcome is the change from baseline to 16 weeks in time to walk 25 feet, measured in seconds.

Baseline and 16 weeks (end of treatment)
Change from baseline in balance (Berg Balance Scale)
기간: Baseline and 16 weeks (end of treatment)

Balance will be assessed using the Berg Balance Scale (BBS), a 14-item performance-based measure of static and dynamic balance. Each item is scored from 0 to 4, and the outcome will be the change from baseline to 16 weeks in the BBS total score (range 0-56), with higher scores indicating better balance and lower risk of falls.

Baseline and 16 weeks (end of treatment)
Change from baseline in fatigue (Fatigue Severity Scale)
기간: Baseline and 16 weeks (end of treatment)

Fatigue will be measured using the Fatigue Severity Scale (FSS), a 9-item questionnaire assessing the impact of fatigue on daily functioning. Each item is rated from 1 to 7, and the outcome will be the change from baseline to 16 weeks in the FSS mean score (range 1-7), with higher scores indicating more severe fatigue.

Baseline and 16 weeks (end of treatment)
Change from baseline in pain (Short-form McGill Pain Questionnaire)
기간: Baseline and 16 weeks (end of treatment)

Pain will be measured using the Short-form McGill Pain Questionnaire (SF-MPQ). The outcome is the change from baseline to 16 weeks in SF-MPQ total score.

Baseline and 16 weeks (end of treatment)

2차 결과 측정

결과 측정
측정값 설명
기간
Change from baseline in cognitive processing speed (Symbol Digit Modalities Test)
기간: Baseline and 16 weeks (end of treatment)

Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). The outcome is the change from baseline to 16 weeks in SDMT total score, with higher scores indicating better processing speed. SDMT scores typically range from 0 to about 110 correct responses.

Baseline and 16 weeks (end of treatment)
Change from baseline in verbal learning and memory (California Verbal Learning Test-II)
기간: Baseline and 16 weeks (end of treatment)

Verbal learning and memory will be assessed using the California Verbal Learning Test-II (CVLT-II). The outcome is the change from baseline to 16 weeks in CVLT-II total recall score, with higher scores indicating better verbal learning and memory. CVLT-II total recall scores typically range from 0 to about 80.

Baseline and 16 weeks (end of treatment)
Change from baseline in visuospatial learning and memory (Brief Visuospatial Memory Test-Revised)
기간: Baseline and 16 weeks (end of treatment)

Visuospatial learning and memory will be assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). The outcome is the change from baseline to 16 weeks in BVMT-R total recall score, with higher scores indicating better visuospatial memory. BVMT-R total recall scores typically range from 0 to 36.

Baseline and 16 weeks (end of treatment)
Change from baseline in depression symptoms
기간: Baseline and 16 weeks (end of treatment)

Depression will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Depression subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in depression total score, with higher scores indicating greater depressive symptoms. Typical depression scales have ranges such as 0-21 (HADS-D) ; enter the exact range that matches the scale you are using.

Baseline and 16 weeks (end of treatment)
Change from baseline in anxiety symptoms
기간: Baseline and 16 weeks (end of treatment)

Anxiety will be measured using a validated questionnaire (e.g., the Hospital Anxiety and Depression Scale-Anxiety subscale or a similar instrument). The outcome is the change from baseline to 16 weeks in anxiety total score, with higher scores indicating greater anxiety. Typical anxiety scales have ranges such as 0-21 (HADS-A) or 0-63 (BAI); enter the exact range that matches the scale you are using.

Baseline and 16 weeks (end of treatment)
Change from baseline in health-related quality of life
기간: Baseline and 16 weeks (end of treatment)

Health-related quality of life will be assessed using a validated questionnaire (e.g., the MSQoL-54 or a comparable instrument). The outcome is the change from baseline to 16 weeks in the quality-of-life total score or composite score. For instruments scored 0-100, higher scores typically indicate better quality of life; specify the exact scoring range and direction according to your chosen measure.

Baseline and 16 weeks (end of treatment)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 11월 1일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2027년 12월 1일

연구 등록 날짜

최초 제출

2025년 10월 2일

QC 기준을 충족하는 최초 제출

2026년 3월 25일

처음 게시됨 (실제)

2026년 3월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 5일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다